Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 50 entries
View as:

Oxybutynin Chloride in Managing Hot Flashes

Phase: N/A Priority: Normal
NCT ID: NCT02961790 Org: User:
Start: 12/09/16 End: 04/27/18 Due: 04/27/19

Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT03334409 Org: User:
Start: 02/16/18 End: 03/13/21 Due: 03/13/22

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05194293 Org: User:
Start: 07/01/23 End: 12/05/28 Due: 12/05/29

Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03080883 Org: User:
Start: 07/14/17 End: 05/09/25 Due: 05/09/26

Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT06160206 Org: User:
Start: 10/02/24 End: 11/30/30 Due: 11/30/31

Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)

Phase: N/A Priority: Normal
NCT ID: NCT04665115 Org: User:
Start: 11/23/20 End: 07/22/22 Due: 07/22/23

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05910801 Org: User:
Start: 01/04/24 End: 12/30/30 Due: 12/30/31

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04659044 Org: User:
Start: 04/01/21 End: 03/29/24 Due: 03/29/25

Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02108782 Org: User:
Start: 10/31/14 End: 05/31/15 Due: 05/31/16

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02368886 Org: User:
Start: 03/27/15 End: 03/02/23 Due: 03/02/24

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03012100 Org: User:
Start: 03/31/17 End: 07/31/26 Due: 07/31/27

Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT03841565 Org: User:
Start: 08/07/20 End: 02/09/22 Due: 02/09/23

Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial

Phase: N/A Priority: Normal
NCT ID: NCT03765736 Org: User:
Start: 04/20/20 End: 12/01/23 Due: 12/01/24

Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03233347 Org: User:
Start: 10/13/17 End: 07/08/25 Due: 07/08/26

Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel

Phase: N/A Priority: Normal
NCT ID: NCT02297412 Org: User:
Start: 11/30/14 End: 07/08/16 Due: 07/08/17

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02037529 Org: User:
Start: 01/17/14 End: 10/31/24 Due: 10/31/25

Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00166439 Org: User:
Start: 03/31/05 End: 09/30/15 Due: 09/30/16

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02393690 Org: User:
Start: 05/04/15 End: 12/31/23 Due: 12/31/24

Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

Phase: N/A Priority: Normal
NCT ID: NCT04096417 Org: User:
Start: 08/31/20 End: 12/01/25 Due: 12/01/26

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04660760 Org: User:
Start: 06/16/21 End: 05/31/26 Due: 05/31/27

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Phase: N/A Priority: Normal
NCT ID: NCT02973997 Org: User:
Start: 02/07/18 End: 10/08/23 Due: 10/08/24

Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel

Phase: N/A Priority: Normal
NCT ID: NCT01637077 Org: User:
Start: 01/31/12 End: 04/30/16 Due: 04/30/17

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Phase: N/A Priority: Normal
NCT ID: NCT05199285 Org: User:
Start: 01/19/23 End: 01/31/27 Due: 01/31/28

White Wine or Nutritional Supplement in Improving Appetite in Patients With Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00936728 Org: User:
Start: 07/31/09 End: 04/17/17 Due: 04/17/18

Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02873195 Org: User:
Start: 07/07/17 End: 12/01/23 Due: 12/01/24